Saturday, 21 July 2018 - 8:35
  • it
  • de
  • en
  • fr


FDA lifts hold for AstraZeneca’s durvalumab

AstraZeneca will resume the clinical trials for durvalumab, one of the most controversial and relevant anti-cancer immunotherapies being studied, as the US regulatory authority lifted the hold on the enrollment of new patients for clinical trials, imposed last month, following…